Lilly Asia Ventures and Johnson & Johnson Innovation – JJDC are both investing in a series A round for the cell therapy developer, a spinoff from Genscript Biotech.
Cowen and European Investment Bank added $52m to a $130m first tranche closed by the AbbVie and Pfizer-backed kidney injury drug developer in July.
The WuXi-backed investment firm returned for a series B2 round that will support phase 1/2 trials for iTeos Therapeutics' oncology therapies.
CapitalG returned for a late-stage round that pushed Collibra’s total funding beyond $345m and boosted its valuation to $2.3bn.
Cisco and Lenovo helped the artificial intelligence software producer hike its valuation from $1.2bn to $2bn, following a $145m round in 2018.
Sistema has participated in a $150m financing round for e-commerce platform developer Ozon having acquired the stake held by fellow corporate MTS last year.
Hillhouse Capital and Chen Yi Investment are making a secondary investment in the Hualan Biological Engineering spinoff which is now valued at more than $1.9bn.
Transportation services provider Via raised the money as part of a series E round also featuring Shell, Hearst Ventures and Mori Building valuing it at $2.25bn.